MTVA · MetaVia Inc. · Executive Compensation
$1.54
+0.00 (+0.00%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due in large part to the ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$10.94M
Shares
6.59M
Volume · Oct 5
53.61K
Avg daily vol (3M)
231.85K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Hyung Heon Kim | President and Chief Executive Officer | $756,328 |
| Marshall H. Woodworth | Chief Financial Officer | $562,985 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Marshall H. Woodworth | Chief Financial Officer | $774,699 |
| Hyung Heon Kim | President and Chief Executive Officer | $716,404 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Hyung Heon Kim | President and Chief Executive Officer | $664,055 |
| Joseph Hooker | Former Interim President and Chief Executive Officer | $432,000 |
| Marshall H. Woodworth | Chief Financial Officer | $154,500 |
| Marshall Woodworth | Chief Financial Officer | $154,500 |
| Gil Price | Former President and Chief Executive Officer | $116,807 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gil Price | Former President and Chief Executive Officer | $501,579 |
| Hyung Heon Kim | President and Chief Executive Officer | $60,880 |
| Joseph Hooker | Former Interim President and Chief Executive Officer | — |
| Marshall Woodworth | Chief Financial Officer | — |
| Marshall H. Woodworth | Chief Financial Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gil Price | Former President and Chief Executive Officer | $920,276 |
| Ben Gil Price | President, and Chief Executive Officer | $920,276 |
| Richard Kang | Former President and Chief Executive Officer | $551,449 |
| Akash Bakshi | Former Chief Operating Officer | $375,000 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Richard Kang | Former President and Chief Executive Officer | $427,308 |
| Dr. Mark Versavel | Former Chief Medical Officer | $357,000 |
| Nicola Shannon | Former Vice President, Clinical Operations | $334,250 |
| Ben Gil Price | President, and Chief Executive Officer | — |
| Gil Price | President, and Chief Executive Officer | — |
| Akash Bakshi | Former Chief Operating Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Nicola Shannon | Former Vice President, Clinical Operations | $66,250 |
| Dr. Mark Versavel | Former Chief Medical Officer | — |
| Richard Kang | President, Chief Executive Officer, Interim Chief Financial Officer, Secretary and Treasurer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James P. Tursi, M.D. | Class I director | Appointed | 2026-06-08 |
| D. Gordon Strickland | Class I director | Appointed | 2026-06-08 |
| Marshall Woodworth | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | Appointed | 2024-03-04 |
| Marshall H. Woodworth | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | Appointed | 2024-03-04 |
| James P. Tursi, M.D. | Class I director | Appointed | 2023-11-06 |
| Marshall H. Woodworth | Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | Appointed | 2023-10-30 |
| Hyung Heon Kim | Chief Executive Officer and President | Appointed | 2023-08-14 |
| Joseph Hooker | Interim Chief Executive Officer | Terminated | 2023-08-14 |
| Hyung Heon Kim | Principal Accounting Officer | Appointed | 2023-08-14 |
| Hyung Heon Kim | Principal Financial Officer | Appointed | 2023-08-14 |
| Hyung Heon Kim | Chief Executive Officer | Appointed | 2023-08-14 |
| Mark A. Glickman | Class III director | Appointed | 2023-05-12 |
| Joseph Hooker | Principal Accounting Officer | Appointed | 2023-01-18 |
| Joseph Hooker | Principal Financial Officer | Appointed | 2023-01-18 |
| Joseph Hooker | Interim Chief Executive Officer and President | Appointed | 2023-01-18 |
| Gil Price, M.D. | Chief Executive Officer and President | Resigned | 2023-01-18 |